4.5 Review

Communicating Benefits from Vaccines Beyond Preventing Infectious Diseases

期刊

INFECTIOUS DISEASES AND THERAPY
卷 9, 期 3, 页码 467-480

出版社

SPRINGER LONDON LTD
DOI: 10.1007/s40121-020-00312-7

关键词

Communication; Direct benefits; Indirect benefits; Vaccination; Vaccines

资金

  1. Fondation Merieux
  2. Sanofi Pasture

向作者/读者索取更多资源

Despite immunisation being one of the greatest medical success stories of the twentieth century, there is a growing lack of confidence in some vaccines. Improving communication about the direct benefits of vaccination as well as its benefits beyond preventing infectious diseases may help regain this lost confidence. A conference was organised at the Fondation Merieux in France to discuss what benefits could be communicated and how innovative digital initiatives can used for communication. During this meeting, a wide range of indirect benefits of vaccination were discussed. For example, influenza vaccination can reduce hospitalisations and deaths in older persons with diabetes by 45% and 38%, respectively, but the link between influenza and complications from underlying chronic non-communicable diseases such as diabetes is frequently underestimated. Vaccination can reduce antimicrobial resistance (AMR), which is growing, by reducing the incidence of infectious disease (though direct and indirect or herd protection), by reducing the number of circulating AMR strains, and by reducing the need for antimicrobial use. Disease morbidity and treatment costs in the elderly population are likely to rise substantially, with the ageing global population. Healthy ageing and life-course vaccination approaches can reduce the burden of vaccine-preventable diseases, such as seasonal influenza and pneumococcal diseases, which place a significant burden on individuals and society, while improving quality of life. Novel disease surveillance systems based on information from Internet search engines, mobile phone apps, social media, cloud-based electronic health records, and crowd-sourced systems, contribute to improved awareness of disease burden. Examples of the role of new techniques and tools to process data generated by multiple sources, such as artificial intelligence, to support vaccination programmes, such as influenza and dengue, were discussed. The conference participants agreed that continual efforts are needed from all stakeholders to ensure effective, transparent communication of the full benefits and risks of vaccination.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Medicine, General & Internal

Exploring the costs of a 13-valent pneumococcal conjugate vaccination program for home care patients

Miika Linna, Juha Laine, Leena Timonen, Heidi Ahman, Myint Tin Tin Htar

CURRENT MEDICAL RESEARCH AND OPINION (2018)

Review Multidisciplinary Sciences

Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies

Myint Tin Tin Htar, Anke L. Stuurman, Germano Ferreira, Cristiano Alicino, Kaatje Bollaerts, Chiara Paganino, Ralf Rene Reinert, Heinz-Josef Schmitt, Cecilia Trucchi, Thomas Vestraeten, Filippo Ansaldi

PLOS ONE (2017)

Article Multidisciplinary Sciences

Tick-borne encephalitis: A 43-year summary of epidemiological and clinical data from Latvia (1973 to 2016)

Dace Zavadska, Zane Odzelevica, Guntis Karelis, Lelde Liepina, Zane Anna Litauniece, Antra Bormane, Irina Lucenko, Jurijs Perevoscikovs, Linda Bridina, Laura Veide, Angelika Krumina, Jelena Storozenko, Wilhelm Erber, Myint Tin Tin Htar, Heinz-Josef Schmitt

PLOS ONE (2018)

Article Immunology

Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe

Laurence Torcel-Pagnon, Vincent Bauchau, Patrick Mahy, Myint Tin Tin Htar, Marianne van der Sande, Cedric Mahe, Tyra Grove Krause, Anne Charrat, Francois Simondon, Xavier Kurz

VACCINE (2019)

Review Immunology

The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review

Myint Tin Tin Htar, Anita H. J. van Den Biggelaar, Heather Sings, Germano Ferreira, Margaret Moffatt, Cassandra Hall-Murray, Thomas Verstraeten, Bradford D. Gessner, Heinz-Josef Schmitt, Luis Jodar

EXPERT REVIEW OF VACCINES (2019)

Review Immunology

The impact of pneumococcal conjugate vaccines on serotype 19A nasopharyngeal carriage

Myint Tin Tin Htar, Heather L. Sings, Maria Syrochkina, Bulent Taysi, Betsy Hilton, Heinz-Josef Schmitt, Bradford D. Gessner, Luis Jodar

EXPERT REVIEW OF VACCINES (2019)

Review Immunology

Serotype evolution in Western Europe: perspectives on invasive pneumococcal diseases (IPD)

Myint Tin Tin Htar, Jose Morato Martinez, Christian Theilacker, Heinz-Josef Schmitt, David Swerdlow

EXPERT REVIEW OF VACCINES (2019)

Article Immunology

Advance system testing: Vaccine benefit studies using multi-country electronic health data - The example of pertussis vaccination

Myint Tin Tin Htar, Maria de Ridder, Toon Braeye, Ana Correa, Chris McGee, Simon de Lusignan, Talita Duarte-Salles, Consuelo Huerta-Alvarez, Elisa Martin-Merino, Lara Tramontan, Giorgia Danieli, Gino Picelli, Nicoline van der Maas, Klara Berencsi, Lisen Arnheim-Dahlstrom, Ulrich Heininger, Hanne-Dorthe Emborg, Daniel Weibel, Kaatje Bollaerts, Miriam Sturkenboom

VACCINE (2020)

Review Public, Environmental & Occupational Health

The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis

M. Tin Tin Htar, M. S. Yerramalla, J. C. Moisi, D. L. Swerdlow

EPIDEMIOLOGY AND INFECTION (2020)

Review Public, Environmental & Occupational Health

Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs

Myint Tin Tin Htar, Sally Jackson, Paul Balmer, Lidia Cristina Serra, Andrew Vyse, Mary Slack, Margarita Riera-Montes, David L. Swerdlow, Jamie Findlow

BMC PUBLIC HEALTH (2020)

Article Infectious Diseases

Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017

Charles Nuttens, Jamie Findlow, Paul Balmer, David L. Swerdlow, Myint Tin Tin Htar

Summary: This study analyzed the evolution of invasive meningococcal disease (IMD) epidemiology in Europe from 2008 to 2017. Overall incidence of IMD decreased, but there were increases in the incidence of serogroups W and Y, as well as in the older population. It is recommended to adjust vaccination strategies based on epidemiological changes.

EUROSURVEILLANCE (2022)

Article Multidisciplinary Sciences

A database study of clinical and economic burden of invasive meningococcal disease in France

Liping Huang, Stephane Fievez, Melanie Goguillot, Lucile Marie, Steve Benard, Anne Elkaim, Myint Tin Tin Htar

Summary: This study examines the clinical characteristics, healthcare resource utilization, and costs associated with invasive meningococcal disease (IMD) in France. The results highlight the severity and economic burden of IMD and emphasize the importance of vaccination for prevention.

PLOS ONE (2022)

Review Public, Environmental & Occupational Health

Epidemiology of invasive meningococcal disease worldwide from 2010-2019: a literature review

Carmen Pardo de Santayana, Myint Tin Tin Htar, Jamie Findlow, Paul Balmer

Summary: This article describes the epidemiology of invasive meningococcal disease (IMD), including its incidence trends and serogroup distribution across different regions and age groups. Data from surveillance reports and published articles from 2010 to 2019 in 77 countries were analyzed, showing a low global incidence of IMD with significant variability in circulating disease-causing serogroups. Infants had the highest incidence, followed by young children, adolescents/young adults, and older adults in some countries. Serogroup B was the predominant cause of IMD globally, but there was a notable increase in cases caused by serogroups W and Y from 2010 to 2019 in several regions, highlighting the unpredictable and dynamic nature of the disease. Serogroups A, B, C, W, and Y accounted for the majority of IMD cases despite the availability of vaccines.

EPIDEMIOLOGY AND INFECTION (2023)

Article Immunology

ADVANCE: Towards near real-time monitoring of vaccination coverage, benefits and risks using European electronic health record databases

Kaatje Bollaerts, Tom de Smedt, Chris McGee, Hanne-Dorthe Emborg, Marco Villa, Maria Alexandridou, Talita Duarte-Salles, Rosa Gini, Claudia Bartolini, Simon de Lusignan, Myint Tin Tin Htar, Lina Titievsky, Miriam Sturkenboom, Vincent Bauchau

VACCINE (2020)

暂无数据